*Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Office of Translational Sciences Office of Clinical Pharmacology (OCP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
This project will be developing quantitative systems pharmacology models that combine pharmacokinetics, pharmacodynamics, and underlying biology to study the efficacy and safety of drugs for various diseases or conditions. Example areas of modeling are: models that combine viral life cycle, human immune responses, and drug actions to predict efficacious drug combinations to treat COVID-19, modeling the relationship between opioid-receptor interactions and respiratory depression.
Under the guidance of a mentor, the participant will learn to develop individual components of mechanistic models, such as pharmacokinetic models, pharmacodynamic models, systems biology models, and combine them into a prediction framework to evaluate drug efficacy/safety in various areas.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2021-0708) in your email.